Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Crinetics Pharmaceuticals, Inc. (CRNX) to Present at 42nd Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that Scott Struthers, Ph.D., founder and chief executive officer of Crinetics, will present at the 42^nd Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 8-11, 2024.

Details of the corporate presentation are as follows:

Date:	Tuesday, January 9, 2024
Time:	3:45 p.m. Pacific Time
Room:	Borgia Room

The live and archived webcast will be accessible on the Events & Presentations page in the Investors section on the Crinetics’ website at www.crinetics.com/events.

If you are interested in arranging a 1×1 meeting with management, please contact your J.P. Morgan representative.

About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Paltusotine, an investigational, first-in-class, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894, a first-in-class, investigational, oral ACTH antagonist, that is currently in Phase 2 clinical studies for the treatment of Cushing’s disease and congenital adrenal hyperplasia. All of the company’s drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease, thyroid eye disease, hyperinsulinism, diabetes and obesity.

Investors:
Chas Schultz
VP, Investor Relations
cschultz@crinetics.com
(858) 450-6464

Corey Davis
LifeSci Advisors
cdavis@lifesciadvisors.com
(212) 915-2577

Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 450-6464 

FAQ

When is Crinetics Pharmaceuticals, Inc. (CRNX) presenting at the 42nd Annual J.P. Morgan Healthcare Conference?

Crinetics Pharmaceuticals, Inc. (CRNX) will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024.

Where is the conference taking place?

The conference is taking place in San Francisco, CA.

How can I access the live and archived webcast of the presentation?

The live and archived webcast will be accessible on the Events & Presentations page in the Investors section on the Crinetics’ website at www.crinetics.com/events.

How can I arrange a 1x1 meeting with Crinetics Pharmaceuticals, Inc. (CRNX) management?

If you are interested in arranging a 1x1 meeting with management, please contact your J.P. Morgan representative.